Date Title Description PDF
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download

Pages

Date Title Description PDF
21 Feb 2023 Annual Corporate Governance Report ROVI releases the 2022 Annual Corporate Governance Report Download
21 Feb 2023 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors Download
16 Feb 2023 On business and financial situation The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. Download
09 Jan 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2022 Download
15 Dec 2022 On Corporate Governance The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages